Cannabis for Crohn’s

“After trying various high cbd to thc ratios of cannabis to treat my Crohn’s disease, and failing, should I try a high THC-only strain?

Not only are there thousands of strains of cannabis, there is a wide assortment of modes of ingestion, and types of refined cannabis medicines.

So you tried a strain heaving in CBD and it didn’t work. Yes you should try a strain heavy in THC and see what happens.

The thing cannabis patients and doctors need to keep in mind is that cannabis works for days, even weeks to reduce pain and inflammation, not just when you’re using it and the effects are very much cumulative, in a good way.

Cannabis is the safest medicine on the planet so, try, try, try again until you find what works for you.

People with Crohn’s or Colitis shouldn’t eat cannabis edibles that aren’t made using a cannabis butter or oil, the ones made with the whole cannabis parts, like leaves will probably be very tough on you, some can’t eat edibles at all but find that refined oils or tinctures provide a lot of relief.

Undiluted THC oils and CBD oils can also be taken rectally, so cannabis, for a Crohn’s and colitis, even cancer patients take it that way since the high doses required can cause significant side effects, even for seasoned medical users.

I don’t think many doctors appreciate the quantity of cannabis needed by Crohn’s and colitis patients, which could be like what someone suffering from debilitating pain would need. Treatment with high doses is not fun, it’s mostly sleep but cannabis does heal and one of the ways it does this, is through restorative sleep. Other medicines just seem to make one condition after another to treat, they call them side-effects but they do seem directly related to the medicines so let’s cut the bull and call them what they are, direct effects and let’s not forget Big pHarm has never found a cure for anything, especially their greed.

Medical dispensaries are like your pharmacy but better in a way, most employees are patients and have personally tried the medicines, or the dispensary has other employees or members with the same conditions and they can share what has worked for them. Cannabis is very personal, it is different for everyone!

Cannabis is the most tweekable medicine, by this I mean, you can take on puff or 100, it’s up to you, what works for you and everyone different.

Did you try refined caps? Oils? Tinctures? Edibles?

You can get refined high CBD and THC heavy capsules for ingestion, some people use them together. GW’s refined cannabis medicine packaged to please the hypocrites and, more importantly the lobbyist, is called Sativex is ~1:1 THC:CBD

Many people have overcome their limitations from Crohn’s and Colitis using cannabis, isn’t time you overcame yours? I did.

Oh, I almost forgot, shouldn’t we study it?!

Thank you Granny Storm Crow!

BOWEL DISORDERS
The Cannabinoid 1 Receptor (CNR1) 1359 G/A Polymorphism Modulates Susceptibility to Ulcerative Colitis and the Phenotype in Crohn’s Disease (full-2010) http://www.ncbi.nlm.nih.gov/pmc/…
The endocannabinoid system links gut microbiota to adipogenesis (full-2010) http://www.ncbi.nlm.nih.gov/pmc/…
Endocannabinoid control of gastric sensorimotor function in man (full-2010) http://onlinelibrary.wiley.com/d…
top
Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus (full–2010) Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus
Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability (full-2010) http://jpet.aspetjournals.org/co…
Small intestinal cannabinoid receptor changes following a single colonic insult with oil of mustard in mice (full–2010) http://journal.frontiersin.org/J…
European Patent Application EP2044935- A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases (full–2010) A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases
Cannabinoids and the gut: New developments and emerging concepts (abst-2010) http://www.ncbi.nlm.nih.gov/pubm…
Gut feelings about the endocannabinoid system (full–2011) http://onlinelibrary.wiley.com/d…
Treatment of Crohn’s disease with cannabis: an observational study (full–2011) http://www.ima.org.il/FilesUploa…
Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis (full–2011) http://www.ncbi.nlm.nih.gov/pmc/…
Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation (full–2011) http://www.nature.com/ajg/journa…
Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full–2011) http://www.ncbi.nlm.nih.gov/pmc/…
Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation (full–2011) http://www.fasebj.org/content/25…
ENDOGENOUS CANNABINOID SYSTEM REGULATES INTESTINAL BARRIER FUNCTION IN VIVO THROUGH CANNABINOID TYPE 1 RECEPTOR ACTIVATION (full–2011) http://ajpgi.physiology.org/cont…
Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity (full–2011) http://www.ncbi.nlm.nih.gov/pmc/…
A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents (full–2011) http://onlinelibrary.wiley.com/d…
US Patent 7884133 B2 Cannabidiol derivatives such as 3-(2,6-dihydroxy-4-pentylphenyl)-4-prop-1-en-2-ylcyclohexene-1-carboxylic acid, used as as analgesics, anti-inflammatory and antidiarrheal agents (full–2011) Patent US7884133 – Pharmaceutical compositions containing (+) cannabidioil and derivatives thereof and some such novel derivatives
Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases (full–2011) http://www.ncbi.nlm.nih.gov/pmc/…
Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability (full–2011) http://www.ncbi.nlm.nih.gov/pmc/…
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation (abst–2011) http://www.ncbi.nlm.nih.gov/pubm…
The effects of cannabidiolic acid and cannabidiol on contractility of the gastro-intestinal tract of Suncus murinus (abst–2011) http://www.unboundmedicine.com/m…
Effects of Cannabinoid Agonists on Sheep Sphincter of Oddi in vitro (abst–2011) http://www.ncbi.nlm.nih.gov/pubm…
Inhibition of cannabinoid metabolic enzymes reduces NSAID-induced gastric pathology (abst–2011) http://www.fasebj.org/cgi/conten…
top
Medical cannabis: the opportunity versus the temptation (abst–2011) http://www.ncbi.nlm.nih.gov/pubm…
Cannabinoid HU210 Protects Isolated Rat Stomach against Impairment Caused by Serum of Rats with Experimental Acute Pancreatitis (full-2012) http://www.plosone.org/article/i…
The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility (full–2012) http://content.karger.com/produk…
The JNK inhibitor XG-102 protects against TNBS-induced colitis (full–2012) http://www.ncbi.nlm.nih.gov/pmc/…
Gut microbiota and the development of obesity (full–2012) http://scielo.isciii.es/scielo.p…
Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice (full–2012) http://www.jleukbio.org/content/…
The effects of fasting duration on gastric emptying in man, an exploration of the role of the endocannabinoid system and inter-individual responsiveness (full–2012) The effects of fasting duration on gastric emptying in man, an exploration of the role of the endocannabinoid system and inter-individual responsiveness – Jones – 2012 – Neurogastroenterology & Motility – Wiley Online Library
Endocannabinoid modulation of jejunal afferent responses to LPS (full–2012) http://onlinelibrary.wiley.com/d…
Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility (full–2012) http://www.jneurosci.org/content…
Evidence for the Putative Cannabinoid Receptor (GPR55)-Mediated Inhibitory Effects on Intestinal Contractility in Mice (full–2012) http://www.ncbi.nlm.nih.gov/pmc/…
Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice (full–2012) http://www.ncbi.nlm.nih.gov/pmc/…
Genetic Epidemiology and Pharmacogenetics in Irritable Bowel Syndrome (full-2012) http://www.ncbi.nlm.nih.gov/pmc/…
Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice (full–2012) http://www.ncbi.nlm.nih.gov/pmc/…
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities (full–2012) http://rstb.royalsocietypublishi…
Cannabinoid signalling regulates inflammation and energy balance: The importance of the brain-gut axis (abst–2012) http://www.ncbi.nlm.nih.gov/pubm…
The Cannabinoid Receptor type 2 Q63R variant increases the risk of celiac disease: Implication for a novel molecular biomarker and future therapeutic intervention (abst–2012) http://www.sciencedirect.com/sci…
The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity (abst–2012) http://www.ncbi.nlm.nih.gov/pubm…
Agents that act luminally to treat diarrhoea and constipation (abst–2012) Agents that act luminally to treat diarrhoea and constipation.
The Dual Effect of Cannabinoid Receptor-1 Deficiency on the Murine Postoperative Ileus (full–2013) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0067427
Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease (full–2013) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0062078
Role of endogenous cannabinoid system in the gut (full–2013) http://www.actaps.com.cn/qikan/manage/wenzhang/2013-4-12.pdf
top
Effect of high fat-diet and obesity on gastrointestinal motility (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890396/
Cannabis Finds Its Way into Treatment of Crohn’s Disease (full–2013) http://www.karger.com/Article/Pdf/356512
Irritable Bowel Syndrome and Migraine: Bystanders or Partners? (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714407/
Cannabinoid Receptor 1 Gene and Irritable Bowel Syndrome: Phenotype and Quantitative Traits (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602676/
Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874007/
Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract (full–2013) http://www.jpp.krakow.pl/journal/archive/04_13/pdf/167_04_13_article.pdf
A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677091/
Repeated Low Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657109/
A potential role for GPR55 in gastrointestinal functions (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660623/
Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: a Prospective Placebo-Controlled Study (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23648372
Acute Δ9-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23769745
Marijuana use patterns among patients with inflammatory bowel disease (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24185313
The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23692073
The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice (full–2013) http://onlinelibrary.wiley.com/d…
Industrial hemp decreases intestinal motility stronger than indian hemp in mice (link to PDF–2013) http://www.europeanreview.org/article/3266
Preventive and therapeutic oral administration of the pentacyclic triterpene α,β-amyrin ameliorates dextran sulfate sodium-induced colitis in mice: The relevance of cannabinoid system (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23454360
Interrogating Therapeutic Manipulation of the Endocannabinoid System in Human Colon (abst–2013) http://www.fasebj.org/cgi/content/meeting_abstract/26/1_MeetingAbstracts/1123.1?sid=eea722c0-971c-4daa-8b8c-38c0c63c19ad
Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23706402
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23849204
Angiotensin II-induced activation of central AT1 receptors exerts Endocannabinoid-mediated gastroprotective effect in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24145131
Magnolol inhibits colonic motility through down-regulation of voltage-sensitive L-type Ca(2+) channels of colonic smooth muscle cells in rats (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23972358
top
Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24238999
Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24275607
Decreased Enteric Fatty Acid Amide Hydrolase Activity is Associated with Colonic Inertia in Slow Transit Constipation (abst–2013) http://onlinelibrary.wiley.com/doi/10.1111/jgh.12346/abstract
Cannabinoid-induced autophagy regulates suppressor of cytokine signaling (SOCS)-3 in intestinal epithelium (full–2014) http://ajpgi.physiology.org/content/307/2/G140
Modulation of Gut-Specific Mechanisms by Chronic Δ9-THC Administration in Male Rhesus Macaques Infected with Simian Immunodeficiency Virus: A Systems Biology Analysis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24400995
Palmitoylethanolamide, a naturally-occurring lipid, is an orally effective intestinal anti-inflammatory agent (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors (full–2014) http://www.ncbi.nlm.nih.gov/pmc/…
GPR18 is required for a normal CD8αα intestinal intraepithelial lymphocyte compartment (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
Chronic administration of Δ9-tetrahydrocannabinol induces intestinal anti-inflammatory microRNA expression during acute SIV infection of rhesus macaques (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24460851
Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides (full–2014) http://onlinelibrary.wiley.com/d…
Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not “higher” (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24641009
Ultramicronized palmitoylethanolamide normalizes intestinal motility in a murine model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1 (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24818658
Palmitoylethanolamide Regulates Development of Intestinal Radiation Injury in a Mast Cell-Dependent Manner (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24848354
Medical Marijuana for Digestive Disorders: High Time to Prescribe? (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
Epigenetic Regulation of Genes that Modulate Chronic Stress-induced Visceral Pain in the Peripheral Nervous System (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
Acute Activation of Cannabinoid Receptors by Anandamide Reduces Gastro-Intestinal Motility and Improves Postprandial Glycemia in Mice (abst-2014) http://www.ncbi.nlm.nih.gov/pubm…
Acute Activation of Cannabinoid Receptors by Anandamide Reduces Gastro-Intestinal Motility and Improves Postprandial Glycemia in Mice (full-2014) http://diabetes.diabetesjournals…
top
Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N palmitoylethanolamine levels and counteracts murine colitis (abst-2014) http://www.ncbi.nlm.nih.gov/pubm…
(Mo1121) Cannabinoid Use Decreases ED Utilization in a Gastroenterology Clinic Population (abst-2014) http://www.gastrojournal.org/article/S0016-5085%2814%2962037-0/pdf
(Mo1122) Prevalence and Characterization of Cannabinoid Use in Patients With Gastrointestinal Disorders (abst–2014) http://www.gastrojournal.org/article/S0016-5085%2814%2962037-0/pdf
Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24444427
Glucose metabolism: Focus on gut microbiota, the endocannabinoid system and beyond (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24631413
Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24813296
The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuroneuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24911079
Potential therapeutic applications of cannabinoids in gastrointestinal and liver diseases: Focus on Δ9-tetrahydrocannabinol pharmacology (abst-2014) http://onlinelibrary.wiley.com/doi/10.1002/9781118451281.ch7/summary
Gut microbiota and obesity: Role in aetiology and potential therapeutic target (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
Colitis generates remote antinociception in rats: the role of the L arginine/NO/cGMP/PKG/KATP pathway and involvement of cannabinoid and opioid systems (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
Role of orphan G protein-coupled receptor 55 in diabetic gastroparesis in mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubm…
Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation (abst–2014)
http://gut.bmj.com/content/63/8/…
Increased Cerebral Cannabinoid-1 Receptor Availability Is a Stable Feature of Functional Dyspepsia: A [F]MK-9470 PET Study (full–2015) http://www.karger.com/Article/Fu…
No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects (full–2015)
http://www.turkjgastroenterol.or…
Gastric mucosal protection: from the periphery to the central nervous system (full–2015) http://www.jpp.krakow.pl/journal…
Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota (full–2015) http://www.ncbi.nlm.nih.gov/pmc/…
The successful use of dronabinol for failure to thrive secondary to intestinal dysmotility (full–2015) http://www.casereports.com/artic…
Pharmacogenetics in irritable bowel syndrome (full–2015) http://informahealthcare.com/doi…
Extraordinary cause of acute gastric dilatation and hepatic portal venous gas: Chronic use of synthetic cannabinoid (full–2015) http://www.wjgnet.com/1007-9327/…
top
Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol (full–2015) Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ 9 -Tetrahydrocannabinol
Monoglyceride lipase-deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity (abst–2015) http://www.ncbi.nlm.nih.gov/pubm…
Self-medication of achalasia with cannabis, complicated by a cannabis use disorder (full–2015) http://www.wjgnet.com/1007-9327/…
A Gut Microbial Metabolite of Linoleic Acid, 10-Hydroxy-cis-12-octadecenoic Acid, Ameliorates Intestinal Epithelial Barrier Impairment Partially via GPR40-MEK-ERK Pathway (abst–2015) http://www.ncbi.nlm.nih.gov/pubm…
Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage (abst–2015) http://www.ncbi.nlm.nih.gov/pubm…
Monoglyceride lipase-deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity (full–2015) Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally-restricted manner (abst–2015) http://www.ncbi.nlm.nih.gov/pubm…
The role of cannabinoids in regulation of nausea and vomiting, and visceral pain (abst-2015) http://www.ncbi.nlm.nih.gov/pubm…
Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation (abst-2015) http://www.ncbi.nlm.nih.gov/pubm…
The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents (abst–2015) http://www.ncbi.nlm.nih.gov/pubm…
The GPR55 antagonist CID16020046 protects against intestinal inflammation (abst-2015) http://www.ncbi.nlm.nih.gov/pubm…
Cannabinoids Regulate Intestinal Motor Function and Electrophysiological Activity of Myocytes in Rodents (abst-2015) http://www.ncbi.nlm.nih.gov/pubm…
Cannabis – therapy for the future? (abst–2015) http://www.ncbi.nlm.nih.gov/pubm…
In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat (abst-2015)
http://www.ncbi.nlm.nih.gov/pubm…
Endocannabinoids and the Digestive Tract and Bladder in Health and Disease (abst–2015) http://www.ncbi.nlm.nih.gov/pubm…
The long-term functional consequences of acute infectious diarrhea (abst–2015) http://www.ncbi.nlm.nih.gov/pubm…
The Endocannabinoid System and Its Role in Regulating the Intrinsic Neural Circuitry of the Gastrointestinal Tract (abst-2015) http://www.ncbi.nlm.nih.gov/pubm…
Endocannabinoids – at the crossroads between the gut microbiota and host metabolism (abst-2015) http://www.ncbi.nlm.nih.gov/pubm…
Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis (abst-2015) http://www.ncbi.nlm.nih.gov/pubm…
Patterns of cannabis use in patients with Inflammatory Bowel Disease: A population based analysis (abst-2015) http://www.ncbi.nlm.nih.gov/pubm…
top
Efficacy, tolerability, and safety of cannabinoids in gastroenterology : A systematic review (abst-2016) http://www.ncbi.nlm.nih.gov/pubm…
RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives (abst–2016) http://www.ncbi.nlm.nih.gov/pubm…


Cannabis heals, isn’t it time?

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Blog at WordPress.com.

Up ↑

%d bloggers like this: